<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE ArticleSet PUBLIC "-//NLM//DTD PubMed 2.7//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/in/PubMed.dtd">
<ArticleSet>
<Article>
<Journal>
				<PublisherName>Isfahan University of Medical Sciences</PublisherName>
				<JournalTitle>Journal of Isfahan Medical School</JournalTitle>
				<Issn>1027-7595</Issn>
				<Volume>29</Volume>
				<Issue>167</Issue>
				<PubDate PubStatus="epublish">
					<Year>2012</Year>
					<Month>01</Month>
					<Day>21</Day>
				</PubDate>
			</Journal>
<ArticleTitle>The Effectiveness of PET-Scan in Diagnosis and Treatment of Non-Small Cell Lung Carcinoma (NSCLC) and Lymphoma: A Comprehensive Review of Literature</ArticleTitle>
<VernacularTitle>The Effectiveness of PET-Scan in Diagnosis and Treatment of Non-Small Cell Lung Carcinoma (NSCLC) and Lymphoma: A Comprehensive Review of Literature</VernacularTitle>
			<FirstPage>2447</FirstPage>
			<LastPage>2456</LastPage>
			<ELocationID EIdType="pii">13641</ELocationID>
			
			
			<Language>FA</Language>
<AuthorList>
<Author>
					<FirstName>Hamid</FirstName>
					<LastName>Ravaghi</LastName>
<Affiliation>Assistant Professor, Department of Health Service Management, School of Management and Medical Information Services, Tehran University of Medical Sciences, Tehran, Iran</Affiliation>

</Author>
<Author>
					<FirstName>Ali</FirstName>
					<LastName>Akbari Sari</LastName>
<Affiliation>Assistant Professor, Department of Health Management and Economics, School of Public Health, And Knowledge Utilization Research Center, Tehran University of Medical Sciences, Tehran, Iran</Affiliation>

</Author>
<Author>
					<FirstName>Sima</FirstName>
					<LastName>Sarvari</LastName>
<Affiliation>Medical Lecturer, Medical College, Shantou University, China</Affiliation>

</Author>
<Author>
					<FirstName>Mohammad Reza</FirstName>
					<LastName>Mobinizadeh</LastName>
<Affiliation>Health Technology Assessment (HTA) Office, Deputy of Curative Affairs, Ministry of Health and Medical Education, Tehran, Iran</Affiliation>

</Author>
</AuthorList>
				<PublicationType>Journal Article</PublicationType>
			<History>
				<PubDate PubStatus="received">
					<Year>2011</Year>
					<Month>08</Month>
					<Day>15</Day>
				</PubDate>
			</History>
		    <Abstract>Background: Positron emission tomography (PET) scan is a non-invasive, complicated and expensive medical imaging technology used for diagnosis and treatment of various diseases including cancers. This study aimed to evaluate the safety and effectiveness of this technology.Methods: The major medical electronic databases including Cochrane Library, Google Scholar, MEDLINE and IranMedex were searched. The studies that compared PET-scan with other diagnostic methods in terms of sensitivity, specificity and safety were considered in this review.Findings: PET-scan has been found to be a non-invasive and safe procedure for diagnosing metastatic NSCLC with a sensitivity and specificity of 74-95% and 81-97%, respectively. On the other hand, the sensitivity and specificity of computed tomography (CT) scan have been reported as 60-67% and 73-77%, respectively. The corresponding values for mediastinoscopy have been 78% and 100%. In lymphoma, the specificity and sensitivity of PET-scan (90% and 79-100%, respectively) have been higher than those of gamma scan. Although PET-scan is not an appropriate method for screening and diagnosis of cancer, it can contribute to staging and follow-up processes in cases of NSCLC and lymphoma. This technology adds 0.046 years (about 17 days) to the patient&#039;s life. Conclusion: PET-scan is a safe technology that has better diagnostic performance in comparison with similar technologies. The application of this method in staging and follow-up of NSCLC and lymphoma can prevent unnecessary surgeries and add a few years to the lives of patients.</Abstract>
			<OtherAbstract Language="FA">Background: Positron emission tomography (PET) scan is a non-invasive, complicated and expensive medical imaging technology used for diagnosis and treatment of various diseases including cancers. This study aimed to evaluate the safety and effectiveness of this technology.Methods: The major medical electronic databases including Cochrane Library, Google Scholar, MEDLINE and IranMedex were searched. The studies that compared PET-scan with other diagnostic methods in terms of sensitivity, specificity and safety were considered in this review.Findings: PET-scan has been found to be a non-invasive and safe procedure for diagnosing metastatic NSCLC with a sensitivity and specificity of 74-95% and 81-97%, respectively. On the other hand, the sensitivity and specificity of computed tomography (CT) scan have been reported as 60-67% and 73-77%, respectively. The corresponding values for mediastinoscopy have been 78% and 100%. In lymphoma, the specificity and sensitivity of PET-scan (90% and 79-100%, respectively) have been higher than those of gamma scan. Although PET-scan is not an appropriate method for screening and diagnosis of cancer, it can contribute to staging and follow-up processes in cases of NSCLC and lymphoma. This technology adds 0.046 years (about 17 days) to the patient&#039;s life. Conclusion: PET-scan is a safe technology that has better diagnostic performance in comparison with similar technologies. The application of this method in staging and follow-up of NSCLC and lymphoma can prevent unnecessary surgeries and add a few years to the lives of patients.</OtherAbstract>
		<ObjectList>
			<Object Type="keyword">
			<Param Name="value">PET-scan</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">NSCLC</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">Lymphoma</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">Imaging</Param>
			</Object>
		</ObjectList>
<ArchiveCopySource DocType="pdf">https://jims.mui.ac.ir/article_13641_27a5eaafdb88c45dd61732d6a6493421.pdf</ArchiveCopySource>
</Article>
</ArticleSet>
